Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
EMBP CRISPR/Cas9 KO Plasmid (m): sc-422395
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- EMBP CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the EMBP genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: EMBP Antibody (F-6): sc-365701
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
EMBP CRISPR/Cas9 KO Plasmid (m) | sc-422395 | 20 µg | $397.00 |
Overview
Prg2 encodes eosinophil major basic protein (EMBP), a highly cationic granule protein expressed in eosinophils that contributes to innate immune effector functions at mucosal and inflammatory sites. Upon degranulation, EMBP can bind negatively charged membranes and extracellular matrix components, influencing epithelial barrier integrity, cytotoxic responses, and tissue remodeling. EMBP activity intersects with pathways governing eosinophil activation, leukocyte recruitment, and inflammatory signaling, making Prg2 a useful marker and mechanistic node in models of allergic inflammation and airway disease. In mouse systems, Prg2 perturbation helps dissect eosinophil-driven immunopathology and host–tissue interactions relevant to chronic inflammatory phenotypes.
EMBP CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Prg2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Prg2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Prg2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish EMBP protein expression.
This CRISPR knockout system enables efficient generation of Prg2-deficient cell models for investigation of EMBP signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Prg2 exon(s) critical for EMBP function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Prg2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by EMBP CRISPR/Cas9 KO Plasmid (m) and EMBP CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Prg2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by EMBP HDR Plasmid (m) and EMBP HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Prg2 homology arms to support homology-directed repair at defined Prg2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.